Chronic motor axonal neuropathy associated with antibodies monospecific for n-acetylgalactosaminyl GD1a

Kaji, Ryuji; Kusunoki, Susumu; Mizutani, Kotaro; Oka, Nobuyuki; Kojima, Yasuhiro; Kohara, Nobuo; Kimura, Jun

doi:10.1002/(sici)1097-4598(200005)23:5<702::aid-mus6>3.0.co;2-a

Cited by 34 publications

(27 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Detection of antibodies against GalNAc-GD1a was useful as a diagnostic marker for autoimmune neuropathies [18,[26][27][28][29], and Boku, OMC-4 and HCA-1 cells would be applicable as sources for preparation of GalNAc-GD1a and as target cells for the detection of anti-GalNAc-GD1a antibodies in sera of patients with autoimmune neuropathies. In fact, in our preliminary experiment, anti-GalNAc-GD1a IgG antibodies could be detected on immunohistochemical staining of Boku cells with sera of patients suffering from chronic motor axonal neuropathy [30].…”

Section: Discussionmentioning

confidence: 63%

Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines

et al. 2016

View full text Add to dashboard Cite

Monoclonal antibody YHD-06 generated by immunization with GM2 reacted with gangliosides with GM2-determinant, i.e., GM2, GalNAc-GM1b and GalNAc-GD1a, among which GalNAc-GD1a was characterized as an antigen of autoimmune peripheral neuropathies including Guillain-Barré syndrome. When glycolipids were examined by TLC-immunostaining with YHD-06 in seven human cervical carcinoma-derived cell lines, GM2 was found in all cell lines, amounting to 15.5 % to 57.5 % of total gangliosides. Whereas GalNAc-GD1a was present in three cell lines, amounting to 5.4-17.5 % of total gangliosides, and GalNAc-GM1b in four cell lines in amounts of less than 2 %. The elevated amounts of gangliosides with GM2 determinant were closely correlated with the relative intensities of gene expression of GalNAc transferase, this being characteristic of cervical carcinoma-derived cells. However, in tissues from patients with several histological types of cervical carcinomas, GM3 was ubiquitously expressed in amounts of more than 66 % of total gangliosides, GM2 was expressed in only five of 15 tissues, and both GalNAc-GM1b and GalNAc-GD1a were not even detected in trace amounts. Since GM1 was detected in all tissues in amounts of less than 0.06 μg/mg dried tissue, all cervical carcinoma tissues were revealed to exhibit GM2 synthesis, indicating that enhanced synthesis of gangliosides with GM2 determinant is a characteristic of cultivated cells in vitro. Similarly, although I(3)SO3-GalCer was not present in the squamous cell carcinoma (SCC) tissues, SCC-derived cells selectively expressed II(3)SO3-LacCer. Since enhanced synthesis of GM2 has been reported in SV-40 virus-transfected fibroblasts, papilloma virus might be involved in the expression of GM2 in cervical carcinoma-derived cells.

show abstract

Section: Discussionmentioning

confidence: 63%

Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Detection of anti-GalNAc-GD1a IgG antibodies was first reported in six patients with GBS after gastrointestinal symptoms [32], and was later confirmed to be associated with preceding C. jejuni infection and primary axonal involvement [33]. These antibodies were also detected in patients with chronic neuropathies such as multifocal motor neuropathy and chronic motor axonal neuropathy [34]. Previous studies suggested that anti-GalNAc-GD1a IgG antibodies disturb the regeneration and maintenance of neurons and neuromuscular transmission in vitro [35,36].…”

Section: Discussionmentioning

confidence: 87%

Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants

et al. 2015

View full text Add to dashboard Cite

Anti-ganglioside autoantibodies of the IgG type are detected in a half of patients with Guillain-Barré syndrome (GBS), and their detection strongly supports the diagnosis of GBS. In contrast, anti-ganglioside IgM antibodies are also often detected in GBS patients, but it remains unclear whether IgM antibodies indicate a diagnosis of GBS. We identified four GBS patients (3.3%) who tested positive for IgM antibodies but negative for IgG antibodies among 122 patients with GBS and its variants. These four patients were all adolescents or young adults (age 13-22 years), experienced preceding gastrointestinal symptoms, and had serological and/or bacterial evidence of recent Campylobacter jejuni enteritis. Serum IgG reacted strongly with the lipo-oligosaccharide (LOS) of the C. jejuni isolates from these patients' stool specimens. Thin-layer chromatography with immunostaining showed that their serum IgG reacted with resorcinol-positive portion of LOS, suggesting that these patients had IgG autoantibodies against sialic acid-containing epitopes, probably unrecognized ganglioside-like structures on the bacterial LOS. We also examined anti-ganglioside autoantibodies in 22 patients with C. jejuni enteritis without subsequent neurological disorders and detected IgM antibodies in seven (32%) patients. Our data indicate that anti-ganglioside IgM antibodies can be detected in C. jejuni enteritis without complication of GBS, and that the detection of anti-ganglioside IgM antibodies does not always support a diagnosis of GBS. IgG autoantibodies against unrecognized gangliosides might play a role in the development of disease in patients with GBS in whom only anti-ganglioside IgM antibodies are detected by routine clinical testing.

show abstract

“…These antibodies were found to cross-react with other gangliosides, most commonly GM2 [11,13]. Kaji and colleagues also recently demonstrated antibodies to GalNAcGD1a without cross-reactivity to GM2 or other gangliosides in three patients with chronic motor axonal neuropathies, including two who improved after intravenous immunoglobulin infusions and cyclophosphamide therapy [14]. However, unlike the patient reported here, these patients had a progressive course that involved more than one extremity clinically and would not meet criteria for benign monomelic amyotrophy.…”

Section: Discussionmentioning

confidence: 49%

IgM antibodies to N-acetylgalactosaminyl GD1a in benign monomelic amyotrophy of the lower limb

Weiss

2005

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Chronic motor axonal neuropathy associated with antibodies monospecific for n-acetylgalactosaminyl GD1a

Cited by 34 publications

References 22 publications

Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines

Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines

Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants

IgM antibodies to N-acetylgalactosaminyl GD1a in benign monomelic amyotrophy of the lower limb

Contact Info

Product

Resources

About